Teva Pharmaceutical Industries (TEVA) Short-Term Debt repayments (2020 - 2023)

Teva Pharmaceutical Industries has disclosed Short-Term Debt repayments across 3 years of filings, most recently posting $500.0 million for Q4 2023.

• Quarterly Short-Term Debt repayments changed N/A year-over-year to $500.0 million in Q4 2023, while the trailing twelve-month figure through Dec 2024 was $700.0 million (down 41.67% YoY) and the FY2023 annual result came in at $700.0 million, changed N/A from the prior year.
• Short-Term Debt repayments advanced to $500.0 million in Q4 2023, from $200.0 million in the prior quarter.
• Over five years, Short-Term Debt repayments peaked at $500.0 million in Q4 2021 and troughed at $200.0 million in Q3 2023.
• A 3-year average of $410.8 million and a median of $471.5 million in 2020 frame the typical range for Short-Term Debt repayments.
• Biggest YoY gain for Short-Term Debt repayments was 12.87% in 2021; the steepest drop was 12.87% in 2021.
• Tracing TEVA's Short-Term Debt repayments over 3 years: stood at $443.0 million in 2020, then rose by 12.87% to $500.0 million in 2021, then changed by 0.0% to $500.0 million in 2023.
• Business Quant data shows TEVA's Short-Term Debt repayments at $500.0 million in Q4 2023, $200.0 million in Q3 2023, and $500.0 million in Q4 2021.